{"id":"experimental-dose-modified-xelox-sintilimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Immune-related adverse events (fatigue, rash, hepatotoxicity)"}]},"_chembl":{"chemblId":"CHEMBL4297829","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T16:10:12.180784","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"XELOX is a combination chemotherapy regimen (capecitabine and oxaliplatin) that damages cancer cell DNA and inhibits proliferation. Sintilimab is a humanized monoclonal antibody that blocks PD-1 on T cells, removing the immune checkpoint that allows tumors to evade immune surveillance. Together, the chemotherapy primes the immune system while sintilimab enhances T-cell activation against tumor antigens.","oneSentence":"Modified XELOX chemotherapy combined with sintilimab (a PD-1 inhibitor) works by killing cancer cells through chemotherapy while simultaneously unleashing the immune system to attack tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:56.342Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric or gastroesophageal junction cancer (Phase 3 trial indication)"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT05918094","phase":"PHASE3","title":"Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-04-30","conditions":"Gastric Cancer","enrollment":540}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental dose: modified XELOX + sintilimab","genericName":"Experimental dose: modified XELOX + sintilimab","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Modified XELOX chemotherapy combined with sintilimab (a PD-1 inhibitor) works by killing cancer cells through chemotherapy while simultaneously unleashing the immune system to attack tumors. Used for Gastric or gastroesophageal junction cancer (Phase 3 trial indication).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}